Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? / Thomas, Peter E.; Vedel-Krogh, Signe; Nordestgaard, Børge G.

I: Current Opinion in Cardiology, Bind 39, Nr. 1, 2024, s. 39-48.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Thomas, PE, Vedel-Krogh, S & Nordestgaard, BG 2024, 'Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?', Current Opinion in Cardiology, bind 39, nr. 1, s. 39-48. https://doi.org/10.1097/HCO.0000000000001104

APA

Thomas, P. E., Vedel-Krogh, S., & Nordestgaard, B. G. (2024). Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? Current Opinion in Cardiology, 39(1), 39-48. https://doi.org/10.1097/HCO.0000000000001104

Vancouver

Thomas PE, Vedel-Krogh S, Nordestgaard BG. Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? Current Opinion in Cardiology. 2024;39(1):39-48. https://doi.org/10.1097/HCO.0000000000001104

Author

Thomas, Peter E. ; Vedel-Krogh, Signe ; Nordestgaard, Børge G. / Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?. I: Current Opinion in Cardiology. 2024 ; Bind 39, Nr. 1. s. 39-48.

Bibtex

@article{e30ed0f1dbc6485ab1aa6d7037014bf9,
title = "Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?",
abstract = "Purpose of review The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity. Recent findings Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025. Summary Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.",
keywords = "aortic valve stenosis, atherosclerotic cardiovascular disease, lipoprotein(a), primary prevention, secondary prevention",
author = "Thomas, {Peter E.} and Signe Vedel-Krogh and Nordestgaard, {B{\o}rge G.}",
note = "Publisher Copyright: {\textcopyright} 2023 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2024",
doi = "10.1097/HCO.0000000000001104",
language = "English",
volume = "39",
pages = "39--48",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?

AU - Thomas, Peter E.

AU - Vedel-Krogh, Signe

AU - Nordestgaard, Børge G.

N1 - Publisher Copyright: © 2023 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2024

Y1 - 2024

N2 - Purpose of review The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity. Recent findings Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025. Summary Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.

AB - Purpose of review The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity. Recent findings Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025. Summary Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.

KW - aortic valve stenosis

KW - atherosclerotic cardiovascular disease

KW - lipoprotein(a)

KW - primary prevention

KW - secondary prevention

U2 - 10.1097/HCO.0000000000001104

DO - 10.1097/HCO.0000000000001104

M3 - Review

C2 - 38078600

AN - SCOPUS:85179643556

VL - 39

SP - 39

EP - 48

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 1

ER -

ID: 377939811